McDonnell Boehnen Hulbert & Berghoff LLP partner Dr. Kevin E. Noonan is quoted in a June 2012 edition of the BIO/Pharmaceutical Outsourcing Report in an article entitled, “Biosimilars Market May Not Be Treasure Trove for CMOs.” The article focuses on FDA guidances published earlier this year that seem to raise at least as many questions as they answer about the agency’s approach to approving biosimilars. View the article